Look up one drug

Apo-Vardenafil · DIN 02471647 Manufacturer: Apotex Inc.; listing date 2019-01-31 Health Canada: Marketed since 2018-12-21 · brand APO-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE) 5 MG · company Apotex inc · schedule Prescription

DIN 02471647: Apo-Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200107; group id 372; item number 0885; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.3203; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471647 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96086

Interchangeable products

Jamp-Vardenafil IR · DIN 02475677 · not recorded Levitra · DIN 02250462 · not recorded Mylan-Vardenafil · DIN 02464209 · not recorded

Shortage status: resolved shortage (ended 2021-10-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471647

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Vardenafil IR · DIN 02475677 Manufacturer: Jamp Pharma Corporation; listing date 2018-12-21 Health Canada: Marketed since 2018-11-01 · brand JAMP-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE) 5 MG · company Jamp pharma corporation · schedule Prescription

DIN 02475677: Jamp-Vardenafil IR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200107; group id 372; item number 0885; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.3203; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475677 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96605

Interchangeable products

Apo-Vardenafil · DIN 02471647 · not recorded Levitra · DIN 02250462 · not recorded Mylan-Vardenafil · DIN 02464209 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475677

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Vardenafil · DIN 02464209 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2018-12-21 Health Canada: Marketed since 2018-11-01 · brand MYLAN-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) 5 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02464209: Mylan-Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200107; group id 372; item number 0885; lccId None; manufacturer id MYL Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.3203; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464209 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95236

Interchangeable products

Apo-Vardenafil · DIN 02471647 · not recorded Jamp-Vardenafil IR · DIN 02475677 · not recorded Levitra · DIN 02250462 · not recorded

Shortage status: active shortage (reported 2026-06-01, estimated to end 2026-10-13, last updated 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02464209

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Vardenafil ODT · DIN 02476088 Manufacturer: Jamp Pharma Corporation; listing date 2019-09-30 Health Canada: Marketed since 2019-06-06 · brand JAMP-VARDENAFIL ODT · ATC G04BE09 VARDENAFIL · form Tablet (orally-disintegrating) · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) 10 MG · company Jamp pharma corporation · schedule Prescription

DIN 02476088: Jamp-Vardenafil ODT Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200110; group id 372; item number 0884; lccId None; manufacturer id JPC Source form: Orally Disintergrating Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $5.8778; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02476088 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96702

Interchangeable products

Staxyn · DIN 02372436 · not recorded

Shortage status: resolved shortage (ended 2022-05-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02476088

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Vardenafil · DIN 02471655 Manufacturer: Apotex Inc.; listing date 2019-01-31 Health Canada: Marketed since 2018-12-21 · brand APO-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE) 10 MG · company Apotex inc · schedule Prescription

DIN 02471655: Apo-Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200108; group id 372; item number 0886; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.3976; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471655 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96087

Interchangeable products

Jamp-Vardenafil IR · DIN 02475685 · not recorded Levitra · DIN 02250470 · not recorded Mylan-Vardenafil · DIN 02464225 · not recorded Vardenafil · DIN 02520397 · not recorded

Shortage status: resolved shortage (ended 2021-10-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471655

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Vardenafil IR · DIN 02475685 Manufacturer: Jamp Pharma Corporation; listing date 2018-12-21 Health Canada: Marketed since 2018-11-01 · brand JAMP-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE) 10 MG · company Jamp pharma corporation · schedule Prescription

DIN 02475685: Jamp-Vardenafil IR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200108; group id 372; item number 0886; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.4019; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475685 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96606

Interchangeable products

Apo-Vardenafil · DIN 02471655 · not recorded Levitra · DIN 02250470 · not recorded Mylan-Vardenafil · DIN 02464225 · not recorded Vardenafil · DIN 02520397 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475685

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mylan-Vardenafil · DIN 02464225 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2018-12-21 Health Canada: Marketed since 2018-11-01 · brand MYLAN-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02464225: Mylan-Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200108; group id 372; item number 0886; lccId None; manufacturer id MYL Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.3976; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464225 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95239

Interchangeable products

Apo-Vardenafil · DIN 02471655 · not recorded Jamp-Vardenafil IR · DIN 02475685 · not recorded Levitra · DIN 02250470 · not recorded Vardenafil · DIN 02520397 · not recorded

Shortage status: resolved shortage (ended 2025-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02464225

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Vardenafil · DIN 02520397 Manufacturer: Sanis Health Inc.; listing date 2021-12-17 Health Canada: Marketed since 2022-03-25 · brand VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) 10 MG · company Sanis health inc · schedule Prescription

DIN 02520397: Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200108; group id 372; item number 0886; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.3976; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520397 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100959

Interchangeable products

Apo-Vardenafil · DIN 02471655 · not recorded Jamp-Vardenafil IR · DIN 02475685 · not recorded Levitra · DIN 02250470 · not recorded Mylan-Vardenafil · DIN 02464225 · not recorded

Shortage status: resolved shortage (ended 2025-06-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520397

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Vardenafil · DIN 02471663 Manufacturer: Apotex Inc.; listing date 2019-01-31 Health Canada: Marketed since 2018-12-21 · brand APO-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE) 20 MG · company Apotex inc · schedule Prescription

DIN 02471663: Apo-Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200109; group id 372; item number 0887; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $11.6811; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471663 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96088

Interchangeable products

Jamp-Vardenafil IR · DIN 02475693 · not recorded Levitra · DIN 02250489 · not recorded Mylan-Vardenafil · DIN 02464233 · not recorded Vardenafil · DIN 02520400 · not recorded

Shortage status: resolved shortage (ended 2021-10-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471663

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Vardenafil IR · DIN 02475693 Manufacturer: Jamp Pharma Corporation; listing date 2018-12-21 Health Canada: Marketed since 2018-11-01 · brand JAMP-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE) 20 MG · company Jamp pharma corporation · schedule Prescription

DIN 02475693: Jamp-Vardenafil IR Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200109; group id 372; item number 0887; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $11.6811; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475693 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96607

Interchangeable products

Apo-Vardenafil · DIN 02471663 · not recorded Levitra · DIN 02250489 · not recorded Mylan-Vardenafil · DIN 02464233 · not recorded Vardenafil · DIN 02520400 · not recorded

Shortage status: resolved shortage (ended 2026-06-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475693

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Vardenafil · DIN 02464233 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2018-12-21 Health Canada: Marketed since 2018-11-01 · brand MYLAN-VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) 20 MG · company Mylan pharmaceuticals ulc · schedule Prescription

DIN 02464233: Mylan-Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200109; group id 372; item number 0887; lccId None; manufacturer id MYL Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $11.6811; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464233 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95240

Interchangeable products

Apo-Vardenafil · DIN 02471663 · not recorded Jamp-Vardenafil IR · DIN 02475693 · not recorded Levitra · DIN 02250489 · not recorded Vardenafil · DIN 02520400 · not recorded

Shortage status: active shortage (reported 2026-06-01, estimated to end 2026-09-18, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02464233

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Vardenafil · DIN 02520400 Manufacturer: Sanis Health Inc.; listing date 2021-12-17 Health Canada: Marketed since 2022-03-25 · brand VARDENAFIL · ATC G04BE09 VARDENAFIL · form Tablet · route Oral · ingredients VARDENAFIL (VARDENAFIL HYDROCHLORIDE TRIHYDRATE) 20 MG · company Sanis health inc · schedule Prescription

DIN 02520400: Vardenafil Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 241200109; group id 372; item number 0887; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $11.6811; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02520400 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100960

Interchangeable products

Apo-Vardenafil · DIN 02471663 · not recorded Jamp-Vardenafil IR · DIN 02475693 · not recorded Levitra · DIN 02250489 · not recorded Mylan-Vardenafil · DIN 02464233 · not recorded

Shortage status: resolved shortage (ended 2025-06-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520400

Shortage record checked 2026-09-13T08:10:21.292534+00:00